arrow
G

Gaetano Finocchiaro

IRCCS Ospedale San Raffaele
H指数:95
被引数:8.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Divergent genomic evolution in astrocytomas and oligodendrogliomas

星形胶质瘤和少突胶质瘤的基因组趋异进化

Nature
IF48.5
2026-10-140
OAAI
ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma

由于miR-205失活导致的ERBB3过表达赋予胶质母细胞瘤对FGF的敏感性、代谢激活以及对ERBB3靶向的易感性

2026-09-100
OAAI
Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial

肿瘤靶向干扰素-α 基因治疗胶质母细胞瘤: 1期试验

2026-06-010
PRE
MEDIAN AND 2 YEARS SURVIVAL OF NEWLY DIAGNOSED UNMETHYLATED MGMT GLIOBLASTOMA PATIENTS TREATED WITH TEMFERON IMMUNO-GENE THERAPY
2024-11-110
PRE
A macrophages-based immunotherapy of solid tumors microenvironment: Preliminary results of the TEM-GBM_01 study
2024-04-050
PRE
Coexisting cancer stem cells with heterogeneous gene amplifications, transcriptional profiles, and malignancy are isolated from single glioblastomas
2023-08-015
OA
Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors
2023-05-043
OAAI
Targeting the tumor microenvironment of glioblastoma multiforme using a macrophage-based treatment for the local delivery of immune-therapeutic payload: The TEM-GBM study (NCT03866109)
2022-09-012
OA
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

替莫唑胺联合nivolumab或安慰剂用于新诊断的MGMT启动子甲基化的胶质母细胞瘤的放化疗的III期试验

2022-05-02246
OAAI
Gamma Knife radiosurgery as primary treatment of low-grade brainstem gliomas: A systematic review and metanalysis of current evidence and predictive factors
2021-12-018
PRE
Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors

立体定向放射外科在免疫治疗时代脑转移治疗中的作用: 对现有证据和预测因素的系统评价

2021-09-0115
PRE
ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma
2021-07-0118
OAAI